Kyle Woodley

Kyle Woodley

Senior Investing Editor, Kiplinger

Kyle Woodley is the Senior Investing Editor of Kiplinger.com. His articles covering stock picks, exchange-traded funds and mutual funds have been featured on MSN, Nasdaq and U.S. News & World Report. He also has appeared on Fox Business Network.

He previously was Managing Editor of InvestorPlace.com, and an award-winning designer and copy editor with Gannett. He also is a graduate of Ohio State University.

Kyle can be reached at kwoodley@kiplinger.com, or you can follow him on Twitter at @KyleWoodley.

Recent Articles

The Wide World of Sports Investing

By Kyle Woodley, Senior Investing Editor, Kiplinger

If you're missing the excitement of sports after Sunday's Super Bowl, the finance world offers you plenty of sports-related stocks ... you just might pick a winner for your portfolio.

Biotech Movers: Keryx Jumps, Sarepta Slips

By Kyle Woodley, Senior Investing Editor, Kiplinger

Among last week's highlights, Keryx jumps on a solid Phase III trial, Sarepta gets pounded from a fake tweet and Halozyme suffers from analyst downgrades.

Barclays CEO Jenkins Buys Goodwill With Common Sense

By Kyle Woodley, Senior Investing Editor, Kiplinger

Antony Jenkins' refusal to accept a bonus may be an obvious PR ploy, but who cares? His nod to the bank's misdeeds is refreshing.

AMZN: The Cult of Not Yet

By Kyle Woodley, Senior Investing Editor, Kiplinger

Amazon keeps climbing on the vague promise of 'someday,' confounding bears and confusing analysts. But our cultural fascination with potential is pervasive ... and it extends far beyond stocks.

Biotech Movers: Arena Gets Warned, MAP Gets an Offer

By Kyle Woodley, Senior Investing Editor, Kiplinger

Among last week's highlights, Europe raises questions about Arena's obesity drug, Belviq, and Allergan offers $958 million for MAP Pharmaceuticals.

Load More